|File:BIBW 2992 structure.svg|
|Systematic (IUPAC) name|
|Molar mass||485.937 g/mol[[Script error: No such module "String".]]|
|Script error: No such module "collapsible list".|
BIBW 2992 (planned trade name Tovok) is a candidate drug against non-small cell lung carcinoma, developed by Boehringer Ingelheim. As of December 2008[update], it is undergoing a Phase III clinical trial for this indication, and Phase II trials for breast, prostate, and head and neck cancers, as well as glioma.
Mechanism of action
Like lapatinib and neratinib, BIBW 2992 is a next generation tyrosine kinase inhibitor (TKI) that irreversibly inhibits human epidermal growth factor receptor 2 (Her2) and epidermal growth factor receptor (EGFR) kinases. BIBW-2992 is not only active against EGFR mutations targeted by first generation TKIs like erlotinib or gefitinib, but also against those not sensitive to these standard therapies. Because of its additional activity against Her2, it is investigated for breast cancer as well as other EGFR and Her2 driven cancers.
Cite error: Invalid
parameter "group" is allowed only.
<references />, or
<references group="..." />
|40px||This antineoplastic or immunomodulatory drug article is a stub. You can help ssf by expanding it.|
- H. Spreitzer (May 13, 2008). "Neue Wirkstoffe - Tovok". Österreichische Apothekerzeitung (in German) (10/2008): 498.
- Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.